Hemoglobinopathy Market, By Test Type (Routine Red Blood Cell (RBC) count, Genetic Testing, Hemoglobin by high performance liquid chromatography, Hemoglobin isoelectric focusing ( Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin solubility test),

Hemoglobinopathy Market, By Test Type (Routine Red Blood Cell (RBC) count, Genetic Testing, Hemoglobin by high performance liquid chromatography, Hemoglobin isoelectric focusing ( Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin solubility test), By Indication (Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia), By End User (Hospitals, Diagnostic Laboratories, Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Hemoglobin is present in the red blood cells that transports oxygen from the lung to the body. Hemoglobinopathy disorder are inherited and are passed on from one generation to another. It is further classified into two categories – 1. Thalassemia Syndrome 2. Structural Hemoglobin Variants. Thalassemia syndrome includes disorder related to synthesis defect. The synthesis defect of alpha globin gives rise to alpha thalassemia and defect in beta globin give rise to beta thalassemia. The structural hemoglobin variants occur due to alteration of alpha and beta chains that causes defect in structure.

Restraints of the Global Hemoglobinopathy Market

High costs, and difficulties associated with diagnosis of hemoglobinopathies such as lack of proper knowledge, and lack of skilled professionals is expected to restrain growth of the market up to certain extent.

Key features of the study:

This report provides in-depth analysis of the global hemoglobinopathy market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global hemoglobinopathy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott Diagnostics, Bio-Rad Laboratories, Inc., Danaher Corp., ReachBio Research Labs, Mindray Medical International Ltd., Nexcelom Bioscience LLC, Nihon Kohden Europe Ltd., PerkinElmer Inc., Siemens Healthineers, and Sysmex Europe GmbH
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global hemoglobinopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

Global Hemoglobinopathy Market, By Test Type:
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
Global Hemoglobinopathy Market, By Indication:
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
Global Hemoglobinopathy Market, By End User:
Hospitals
Diagnostic Laboratories
Clinics
Global Hemoglobinopathy Market, By Geography:
North America
By Test Type
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
By Indication
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
By End User
Hospitals
Diagnostic Laboratories
Clinics
By Country:
U.S.
Canada
Europe
By Test Type
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
By Indication
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
By End User
Hospitals
Diagnostic Laboratories
Clinics
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Test Type
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
By Indication
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
By End User
Hospitals
Diagnostic Laboratories
Clinics
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Test Type
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
By Indication
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
By End User
Hospitals
Diagnostic Laboratories
Clinics
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Test Type
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
By Indication
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
By End User
Hospitals
Diagnostic Laboratories
Clinics
By Country:
GCC
Israel
Rest of Middle East
Africa
By Test Type
Routine Red Blood Cell (RBC) count
Genetic Testing
Hemoglobin by high performance liquid chromatography
Hemoglobin isoelectric focusing ( Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin solubility test
By Indication
Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia
By End User
Hospitals
Diagnostic Laboratories
Clinics
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Abbott Diagnostics *
Company Overview
Test Portfolio
Financial Performance
Key Strategies
Recent Developments
Bio-Rad Laboratories, Inc.
Danaher Corp.
ReachBio Research Labs
Mindray Medical International Ltd.
Nexcelom Bioscience LLC
Nihon Kohden Europe Ltd.
PerkinElmer Inc.
Siemens Healthineers
Sysmex Europe GmbH

“*” marked represents similar segmentation in other categories in the respective section.